Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

This study tests a drug called sacituzumab tirumotecan in 30 people with advanced pancreatic cancer that has worsened after at least one prior treatment. The drug is given by IV every two weeks and aims to shrink tumors or slow the disease. Researchers will also check how well th…

This early-stage study tests a new gene-editing drug called EDB-102 in 15 adults with advanced non-small cell lung cancer that has spread to the liver and is no longer responding to standard targeted therapy. The drug uses CRISPR technology to find and disable a specific cancer-c…

This study tests whether giving a short course of radiation together with immunotherapy before surgery can help people with a rare type of cancer called retroperitoneal sarcoma. About 28 adults whose tumors are hard to remove completely will receive this combination treatment. Th…

This study tests a new drug combination for women with cervical cancer that has returned or spread and no longer responds to standard immunotherapy. About 25 participants will receive a dual-targeting immunotherapy plus chemotherapy, with or without an anti-growth drug, for up to…

This study tests a shorter, more intense radiation schedule (hypofractionated radiotherapy) for people with intermediate-risk head and neck cancer who have had surgery. The goal is to see if this approach is safe and effective at preventing cancer from coming back. About 60 adult…

This early-phase study tests a new cell therapy called NEUK203-13 in up to 9 people with advanced small cell lung cancer or neuroendocrine tumors that have stopped responding to standard treatments. The therapy uses specially engineered immune cells (CAR-NK) made from stem cells,…

This study tests a personalized approach for HER2-positive breast cancer, where treatment is adjusted based on each patient's genetic and molecular profile. The goal is to improve cure rates while reducing harsh side effects from standard chemotherapy. About 2,000 women with earl…

This study tests two experimental drugs, Glecirasib and Ivonescimab, together as a first treatment for people with a specific type of advanced lung cancer (KRAS G12C mutation, PD-L1 positive). The goal is to see if the combination is safe and can shrink tumors. About 42 adults wi…

This study tests a new type of radiation therapy that uses daily MRI scans to track brain tumors and adjust the radiation beam in real time. It aims to improve control of large or tricky brain metastases while reducing side effects like brain tissue damage. About 200 adults with …

This early-phase study tests a new treatment called CAR-Macrophage therapy for people with advanced solid tumors that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells based on specific marke…

This study looks at whether women with intermediate-risk breast cancer can safely avoid radiation therapy to the lymph nodes after surgery. About 3,100 participants will be randomly assigned to receive either standard radiation or no radiation. The goal is to see if skipping radi…

This study tests whether adding the drug adebrelimab to standard chemoradiotherapy helps people with large, stage III lung cancer that can't be surgically removed. About 204 adults aged 18-75 with good performance status will be enrolled. The main goal is to see if the combinatio…

This study tests a new drug combination (fruquintinib plus trifluridine/tipiracil) against a standard combo (bevacizumab plus trifluridine/tipiracil) in people with advanced colorectal cancer that has not responded to standard chemotherapy. About 292 adults aged 18-75 will take p…

This early-stage study tests a new drug (BRII-5395) combined with two approved cancer treatments for people with advanced liver cancer linked to hepatitis B. The main goal is to check safety and find the right dose. About 21 participants who have already tried other treatments wi…

This study tests whether adding a new drug (QL1706) to standard chemotherapy helps people with advanced triple-negative breast cancer live longer without their disease getting worse. About 78 adults who have already tried one or two prior treatments will be randomly assigned to g…

This study tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemoradiotherapy can help people with locally advanced esophageal cancer whose prior chemo-immunotherapy did not work. About 40 adults aged 18-75 will receive the treatment, and…

This study tests whether adding an immunotherapy drug (Aitua Combination Antibody) to standard chemotherapy before surgery helps remove more advanced ovarian cancer. About 82 people with stage IIIC-IV high-grade serous ovarian cancer who cannot have optimal initial surgery will b…

This early study tests a new treatment called CAT-101, made from a patient's own immune cells trained to attack cancer cells with specific KRAS mutations. It is given alone or with another drug (tislelizumab) to people with advanced pancreatic cancer or other solid tumors. The ma…

This study tests a combination of a targeted drug (zorifertinib) and chemotherapy given directly into the fluid around the brain for people with a type of lung cancer that has spread to the lining of the brain. The goal is to control the disease and improve survival. About 38 adu…

This study tests new anti-cancer drugs and technologies in 600 people with rare advanced solid tumors that have stopped responding to standard treatments. Participants receive therapies matched to their tumor's unique genetic profile. The goal is to see if these treatments are sa…

This early-stage trial tests a new drug called BR101 injection in 10 adults with multiple myeloma that has returned or not responded to prior treatments. The main goals are to find the safest dose and check for side effects. Researchers will also look at whether the drug helps sh…

This study tests a new drug called MTM-H-001 in adults with certain blood cancers (like diffuse large B-cell lymphoma and chronic lymphocytic leukemia) that have not responded to or returned after standard treatments. The main goal is to check the drug's safety and find the right…

This study tests a combination of three drugs (sintilimab, surufatinib, and temozolomide) in 32 people with advanced neuroendocrine carcinoma that has worsened after prior treatment. The goal is to see if the combination can shrink tumors or stop them from growing. Participants r…

This study tests whether adding the immunotherapy drug adebrelimab and/or the targeted drug SHR-A1811 to standard chemotherapy can help more people with HR-positive, HER2-low early breast cancer achieve a complete response (no cancer found at surgery). About 249 participants will…

This study tests whether giving a combination of chemotherapy (nab-paclitaxel and cisplatin) plus an immunotherapy drug (sintilimab) before surgery can improve outcomes for people with locally advanced cervical cancer. The approach is compared to standard chemoradiotherapy. About…

This study looks at people with stage II-IIIB non-small cell lung cancer whose tumors shrank after immunotherapy. It compares two surgery approaches: removing less lung tissue (to preserve lung function) versus the standard larger removal. The goal is to see if the smaller surger…

This study tests whether adding radiotherapy to chemotherapy before surgery can help shrink tumors and improve outcomes for people with locally advanced breast cancer. About 50 participants with Luminal or triple-negative breast cancer that didn't shrink enough after initial chem…

This study tests a drug called darolutamide, given with or without hormone therapy, before surgery for high-risk prostate cancer. About 60 men will receive the treatment for 3-6 months, then have their prostate removed. The goal is to see if the drug can reduce cancer cells left …

This study tests a symptom management program for 252 people recovering from esophageal cancer surgery. The program uses a guide to help patients and doctors track and treat symptoms early. The goal is to reduce serious complications and improve quality of life after surgery.

This study tests whether it is safe to avoid placing a nasogastric tube (a tube through the nose into the stomach) after minimally invasive pancreatic surgery. About 200 adults aged 18-75 will be randomly assigned to either routine tube placement or no tube. The goal is to see if…

This study tests if a daily whey protein drink can lower the chance of severe, painful mouth sores caused by radiation therapy in people with head and neck cancer. About 504 adults will either get the protein supplement or a placebo during their radiation treatment. Researchers w…

This study looks at how the immune system changes in people with muscle-invasive bladder cancer after they receive treatment before surgery. Researchers will study 30 participants to find markers that can predict if the treatment worked well. The goal is to use this information t…

This study will test a new AI tool called BaiXiaoAi that helps cancer patients, their families, and doctors stay in touch. About 300 adults with cancer will use a special WeChat group where the AI answers questions and shares helpful information. The goal is to see if the AI is a…

This study looks at where colorectal cancer spreads to lymph nodes in 1200 patients. Researchers want to find patterns that could help doctors better plan treatment. Participants will have their removed lymph nodes analyzed and be followed for at least 5 years after surgery.

This study aims to better understand kidney cancer by examining different nodules within the same tumor. Researchers will analyze tissue from 10 patients to see how these nodules differ genetically and how they respond to drugs in lab-grown 3D models. The goal is to uncover why s…